



(11) **EP 1 897 881 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

(15) Correction information:
Corrected version no 1 (W1 A2)
Corrections, see
Bibliography INID code(s) 84

(51) Int Cl.:
C07D 471/04 (2006.01) **C07D 495/04** (2006.01)
A61P 3/00 (2006.01) **A61K 31/4365** (2006.01)

(48) Corrigendum issued on:
11.08.2010 Bulletin 2010/32

(43) Date of publication:
12.03.2008 Bulletin 2008/11

(21) Application number: **07122274.9**

(22) Date of filing: **19.06.2003**

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
Designated Extension States:
LV

(30) Priority: **20.06.2002 SE 0201925**
11.07.2002 SE 0202181
26.08.2002 US 406120 P
01.10.2002 SE 0202908
17.12.2002 US 434010 P
10.02.2003 SE 0300357
23.04.2003 US 464701 P

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
03760999.7 / 1 513 828


(71) Applicant: **Biovitrum AB (publ)**
112 76 Stockholm (SE)

(72) Inventors:
• **Johansson, Gary**
169 66, SOLNA (SE)
• **Jenmalm Jensen, Annika**
756 45, UPPSALA (SE)
• **Beierlein, Katarina**
756 55, UPPSALA (SE)

Remarks:
This application was filed on 04-12-2007 as a divisional application to the application mentioned under INID code 62.

(54) **Compounds useful for the treatment of obesity, type II diabetes and CNS disorders**

(57) The present invention relates to compounds of the general formula (I),



(I)

wherein P is sulfone or sulfonamide; and A, B, W, X, Y and R³ are as defined in the description; to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes, and/or CNS disorders, to achieve reduction of body weight and of body weight gain.

EP 1 897 881 A8